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Abstract
Background: In January 2003, STAndards for the Reporting of Diagnostic accuracy studies (STARD) were published in
a number of journals, to improve the quality of reporting in diagnostic accuracy studies. We designed a study to
investigate the inter-assessment reproducibility, and intra- and inter-observer reproducibility of the items in the STARD
statement.
Methods: Thirty-two diagnostic accuracy studies published in 2000 in medical journals with an impact factor of at least
4 were included. Two reviewers independently evaluated the quality of reporting of these studies using the 25 items of
the STARD statement. A consensus evaluation was obtained by discussing and resolving disagreements between
reviewers. Almost two years later, the same studies were evaluated by the same reviewers. For each item, percentages
agreement and Cohen's kappa between first and second consensus assessments (inter-assessment) were calculated.
Intraclass Correlation coefficients (ICC) were calculated to evaluate its reliability.
Results: The overall inter-assessment agreement for all items of the STARD statement was 85% (Cohen's kappa 0.70)
and varied from 63% to 100% for individual items. The largest differences between the two assessments were found for
the reporting of the rationale of the reference standard (kappa 0.37), number of included participants that underwent
tests (kappa 0.28), distribution of the severity of the disease (kappa 0.23), a cross tabulation of the results of the index
test by the results of the reference standard (kappa 0.33) and how indeterminate results, missing data and outliers were
handled (kappa 0.25). Within and between reviewers, also large differences were observed for these items. The inter-
assessment reliability of the STARD checklist was satisfactory (ICC = 0.79 [95% CI: 0.62 to 0.89]).
Conclusion: Although the overall reproducibility of the quality of reporting on diagnostic accuracy studies using the
STARD statement was found to be good, substantial disagreements were found for specific items. These disagreements
were not so much caused by differences in interpretation of the items by the reviewers but rather by difficulties in
assessing the reporting of these items due to lack of clarity within the articles. Including a flow diagram in all reports on
diagnostic accuracy studies would be very helpful in reducing confusion between readers and among reviewers.
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Background
Over the past ten years, awareness of the importance of
the quality of reporting of research articles has increased.
Many systematic reviews have emphasized the poor qual-
ity of research reports. [1-3] Important aspects of design
and results, such as a patient flow and adverse events, are
often lacking in primary research articles. [1,3-7] To rem-
edy this, guidelines have been developed to improve the
reporting of randomised controlled trials (CONSORT),
diagnostics accuracy studies (STARD), systematic reviews
of randomised controlled trials (QUOROM) and observa-
tional studies (MOOSE). [8-14] Recently, also a checklist
for STrengthening the Reporting of OBservational studies
in Epidemiology (STROBE) has been developed. [15]
After the publication of the CONSORT statement in 1996,
Moher et al. evaluated the quality of reporting in 211 ran-
domised controlled trails published in British Medical
Journal, the Journal of the American Medical Association, the
Lancet, and the New England Journal of Medicine by using
the CONSORT checklist. [16] They concluded that the use
of the CONSORT statement was associated with improve-
ments in the quality of reporting of randomised control-
led trials [16]. The presentation of a flow diagram also
improved the quality of reporting of randomised control-
led trials. [17]
In January 2003, guidelines for the reporting of studies on
diagnostic accuracy (STARD statement) were published
simultaneously in eight medical journals (Radiology,
American Journal of Clinical Pathology, Annals of Internal
Medicine, British Medical Journal, Clinical Biochemistry,
Clinical Chemistry, Clinical Chemistry of Laboratory Medi-
cine, and Lancet). The STARD statement contains a list of
25 items and encourages the use of a flow diagram to rep-
resent the design of the study and the flow of patients
through the study. [11,12] These items were identified by
an extensive search in the literature by the STARD steering
committee and subsequently reviewed during a two-day
consensus meeting with researchers, editors, and mem-
bers of professional organizations. [11,12] Although the
STARD statement was piloted for a number of months,
there was no formal evaluation of its applicability.
Recently, we have evaluated the quality of reporting of
124 diagnostic accuracy studies published in 2000 (Pre-
STARD evaluation) in 12 medical journals, using the
items of the STARD statement. [18] We concluded that the
quality of reporting in diagnostic accuracy articles is less
than optimal, even in journals with an impact factor
above 4. [18]
In order to evaluate the improvement of the quality of
reporting of diagnostic accuracy studies published after
the STARD statement, knowledge of the reproducibility of
the assessment of the STARD checklist is needed. In addi-
tion, reproducibility of the individual STARD items gives
input to the potential future adaptation or rewording of
the STARD statement. Therefore, a reproducibility study
was carried out within the evaluation study of the STARD
statement. Our objective was to investigate the inter-
assessment reproducibility of evaluating the quality of
reporting of diagnostic accuracy studies published in
2000, using the items of the STARD statement. In addi-
tion, the intra- and inter-observer reproducibility was cal-
culated to gain more insight into the sources of variation.
Methods
Selection of studies
Eligible papers for this reproducibility study were studies
on diagnostic accuracy published in 2000 in one of the
following 12 journals: Annals of Internal Medicine,
Archives of Internal Medicine, Archives of Neurology,
BMJ, Circulation, Clinical Chemistry, Gut, JAMA, Lancet,
New England Journal of Medicine, Neurology, Radiology.
These journals were selected based on the number of diag-
nostic accuracy studies published in 2000 and their
impact factor (≥ 4). [18] The papers published in these
journals had been included in a pre-STARD evaluation
study, described elsewhere. [18]
An independent referee (ML, see acknowledgements)
selected 32 out of 124 eligible diagnostic accuracy studies
published in 2000. This referee had not been involved in
any of the assessments. In making the selection, the refe-
ree took into account the quality of the reporting of the
studies in order to ensure variability: half of the studies
reported more than half of STARD items, the other half
did not. Other selection criteria were a representative dis-
tribution of journals and an equal distribution of studies
between the second reviewers.
Study procedures
An overview of the design of this reproducibility study is
presented in Figure 1. The items of the STARD statement
were used to assess the quality of reporting. The reviewers
determined for each item whether it was adequately
described in the text. Note that the reviewers were not
evaluating the likelihood of bias, but only the quality of
reporting.
During the first assessment, between March 2003 and
May 2003 (Pre-STARD evaluation), two reviewers inde-
pendently evaluated the quality of reporting in the
included articles. One reviewer (NS) assessed all 32 arti-
cles and four other reviewers (AWSR, DAWMW, RWJGO,
and HCWV) each evaluated a quarter of all the articles.
Disagreements were discussed and resolved in a consen-
sus meeting. If consensus could not be reached, a third
reviewer made the final decision. All five reviewers areBMC Medical Research Methodology 2006, 6:12 http://www.biomedcentral.com/1471-2288/6/12
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Overview of the design of the reproducibility study Figure 1
Overview of the design of the reproducibility study. * Papers were included in the pre-STARD evaluation, described elsewhere 
[18], † Four reviewers (AWSR, DAWMW, RWJGO, and HCWV) acted as second reviewer and each evaluated 8 articles. At 
the second assessment, the same reviewers evaluated the same studies, ‡ The first assessment was carried out together with 
the pre-STARD evaluation (March – May 2003), ¶The second assessment was carried out together with the post-STARD eval-
uation (January – March 2005).
Diagnostic accuracy studies published 
in 2000 in general medical and disease 
specific journals (n=124)* 
Selection of diagnostic accuracy 
studies (n=32) for reproducibility 
study 
Consensus between reviewer I and II 
about the quality of reporting of 
diagnostic accuracy studies (n=32) 
Consensus between reviewer I and II 
about the quality of reporting of 
diagnostic accuracy studies (n=32) 
Reviewer I performed 
evaluation of quality of 
reporting  (n=32) 
Reviewer II performed  
evaluation of quality of 
reporting (n=32)† 
Reviewer II performed  
evaluation of quality of 
reporting (n=32)†  
Reviewer I performed 
evaluation of quality of 
reporting  (n=32) 
Inter-observer reproducibility
FIRST ASSESSMENT‡
SECOND ASSESSMENT¶
Inter-observer reproducibility
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clinical epidemiologists and have experience in reviewing
clinical articles.
During the second assessment (between January 2005
and March 2005), this procedure was repeated in the
same sample of 32 studies. To enable assessment of intra-
observer reproducibility, each study was assessed by the
same two reviewers. The second assessment was carried
out together with the Post-STARD evaluation; studies
published in 2004 (data not shown).
Statistical analysis
For each item in the STARD-statement, the total number
of articles (%) reporting that item was calculated.
For the quantification of the reproducibility, three types of
analysis were applied: Cohen's kappa statistics and the
Bland and Altman method for assessing agreement and
the Intraclass Correlation Coefficient (ICC) for the evalu-
ation of reliability. Agreement provides insight into the
distribution of differences between observers (or assess-
ments), whereas reliability provides information on the
ability of two observers (assessments) to differentiate
between papers with high or poor quality of reporting.
To evaluate the inter-assessment agreement, we calculated
percentages agreement between the first and second
assessment and Cohen's kappa statistics for each item of
the STARD-statement. A kappa value > 0 represents the
observed agreement above chance agreement, where a
value of 1 represents perfect agreement between reviewers
or assessments. [19] To interpret the estimated kappa val-
ues, we used the classification suggested by Landis and
Koch, indicating the strength of agreement: poor (kappa <
0.00), slight (kappa 0.00–0.20), fair (0.21–0.40), moder-
ate (0.41–0.60), substantial (0.61–0.80), and almost per-
fect (0.81–1.00). [20]
For each assessment, we counted the total number of
reported items in each article (range 0 to 25). As six items
(items 8, 9, 10, 11, 13, 24) concern index tests as well as
the reference standard, we counted the index test as 1/2
item and the reference standard as 1/2 item. The mean
number of items and standard deviation were calculated
for each assessment.
For the quantification of inter-assessment reproducibility
of the total number of STARD items, we used the Bland
and Altman method for evaluating agreement between
the first and second assessment and the Intraclass Correla-
tion Coefficients (ICC) for an evaluation of the reliability.
[21]
The Bland and Altman method describes the distribution
of differences in number of reported STARD items
between the first and second assessment. Inter-assessment
agreement was quantified by calculating the mean differ-
ence (d) of the number of STARD items reported between
the first and second assessment and its standard deviation
(SD) for this difference. The closer d is to zero and the
smaller the SD of this difference, the better the inter-
assessment agreement. Differences between the first and
second assessment were plotted against the mean number
of reported STARD items of the two assessments. This
graph shows the size, direction, and range of the differ-
ences and shows whether differences between assess-
ments are consistent across the range of total number of
STARD items reported. The 95% limits of agreement were
calculated as the mean difference between the first and
second assessment ± 1.96 SD of the differences, indicating
the total error (bias and random error together). The pres-
ence of bias between both assessments was estimated by
calculating the 95% confidence interval (95% CI) for d.
The 95% confidence interval for d was calculated as d ±
1.96 * [SDdiff/√ n], where n is the number of articles
included in this study. If zero lies outside the 95% CI, sys-
tematic differences (bias) between the observers exist.
[21]
When trying to determine whether introduction of the
STARD statement has improved the quality of reporting,
this change must overcome the measurement error, ie. be
larger than the smallest detectable difference (SDD). The
SDD was calculated as 1.96 * SDdiff, in which SDdiff repre-
sents the standard deviation of the difference between the
measurement values of the first and second assessment.
[22]
The ICC provides information on the ability to differenti-
ate between articles with regard to quality of reporting
(reliability). The ICC was defined as the ratio of variance
in quality of reporting of articles (article variability) over
the total variance (including article variability, assessment
variability, random error variability). The ICC takes values
in the range of 0 (no reliability) to 1 (perfect reliability).
An ICC of less than 0.75 was considered unsatisfactory.
[23] Two-way random effect models were used to calcu-
late ICCs according to Fleiss. [19] Data-entry and statisti-
cal analysis using SPSS for Windows (Release 11.0.1,
2001) were done by NS.
In addition, for each item of the STARD statement, the
intra-observer agreement before consensus was evaluated
for the first (NS) and second reviewer separately. Note
that, the second review was carried out by four different
reviewers (AWSR, DAWMW, RWJGO, HCWV), each
reviewer evaluating eight of the 32 articles.BMC Medical Research Methodology 2006, 6:12 http://www.biomedcentral.com/1471-2288/6/12
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Furthermore, the inter-observer agreement (first versus
second reviewer) was calculated for both assessments to
study whether reviewers interpreted items differently.
The a priori calculation of the number of articles to be
included in the evaluation was based on a paired t-test for
a difference of one item between the means of two assess-
ments, expecting a standard deviation of the difference
between assessments of 2 items. Using a two-tailed α of
0.05, a total of 32 articles would be required to achieve a
power of 80%.
Results
Study characteristics
The 32 diagnostic accuracy studies published in 2000
included 25 cohort and 7 case control studies. Ten articles
were published in a general medical journal (Annals of
Internal Medicine (n = 3), Archives of Internal Medicine
(n = 1), British Medical Journal (n = 2), Journal of the
American Medical Association (n = 4)) and 22 in disease
or discipline specific journals (Archives of Neurology (n =
2), Circulation (n = 4), Clinical Chemistry (n = 4), Gut (n
= 4), Neurology (n = 4) and Radiology (n = 4)). In most
studies, the diagnostic accuracy of laboratory tests (n =
14) or imaging tests (n = 17) was examined. In only one
study, the diagnostic value of history taking and physical
examination was investigated. There was a large variety in
the target conditions described in the studies, which
included Pompe disease, deep vein thrombosis, acute
stroke, colorectal neoplasia, colbalamin deficiency, cervi-
cal cancer, extra temporal lobe epilepsy in children, skele-
tal dysplasia, pulmonary embolism, and obstructive
airways diseases.
Inter-assessment reproducibility
Reporting of STARD items
The results of the quality of reporting for both assessments
and the percentage of agreement for each item of the
STARD statement between the first and second assessment
are presented in Table 1. There was a large variation in the
quality of reporting of the items of the STARD statement.
Some items (item 25) were reported by almost all articles,
whereas other items (item 1, item 13b, 24b) were rarely
positively evaluated.
The overall inter-assessment agreement for all items of the
STARD statement was 85% (Cohen's kappa 0.70), and
varied from 63% (item 18) to 100% (items 14, 20 and
flow diagram). The largest differences (≤ 75 % agreement
and Cohen's kappa ≤ 0.40) between the two assessments
were found for the description of the rationale of the ref-
erence standard (item 7), the number of included partici-
pants that underwent tests and description why
participants failed to undergo either test (item 16), the
distribution of the severity of the disease in those with the
target condition and other diagnosis in participants with-
out the target condition (item 18), a cross tabulation of
the results of the index test by the results of the reference
standard (item 19), and the reporting how indeterminate
results, missing data and outliers of the index test were
handled (item 22). In accordance with the inter-assess-
ment agreement for the above-mentioned items, a
Cohen's kappa between 0.21 and 0.40 was observed,
which means 'fair' according the classification of Landis
and Koch. [20] In contrast, the inter-assessment agree-
ment for the discussion of the clinical applicability of
study findings (item 25) was quite high (94%), but the
kappa statistics was poor (< 0.00). This low kappa can be
explained by the high prevalence (97%) of reporting this
item in the articles, indicating that it is an item that can be
agreed on easily. [24]
Reporting of number of STARD items per article
Table 2 summarizes the results of the inter-assessment
agreement of the total number of reported STARD items.
The mean number of reported items was 12.3 items per
article. None of the articles included a flow diagram.
Figure 2 shows the Bland and Altman plot with differ-
ences between the two assessments on the y-axis and the
mean number of reported STARD items of the two assess-
ments on the x-axis. The mean number of STARD items
reported varied from 5.3 to 18.5 items. We found a small
but non-significant difference between the first and the
Differences between first and second assessment for each  article (n = 32), plotted against the mean value of both  assessments for the total number of reported STARD items Figure 2
Differences between first and second assessment for each 
article (n = 32), plotted against the mean value of both 
assessments for the total number of reported STARD items. 
Solid line: mean difference (0.39) between the two assess-
ments, short striped lines: 95% Confidence Intervals (-0.4, 
1.2) of systematic differences, long striped lines: 95% limits of 
agreement (-4.3, 5.0).BMC Medical Research Methodology 2006, 6:12 http://www.biomedcentral.com/1471-2288/6/12
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Table 1: Number of articles reported the items of the STARD statement at the first and second assessment and for each item the 
percentage agreement between the two assessments and kappa statistics of the two assessments.*
First 
assessment
(n = 32)
Second 
assessment
(n = 32)
Inter-
assessment 
agreement
Cohen's 
kappa
Item n (%) n (%) n (%)
Title/abstract/keywords
1 Identify the article as a study of diagnostic accuracy (recommend MeSH heading 
'sensitivity and specificity').
3 (9) 1 (3) 94 0.48
Introduction
2 State the research questions or study aims, such as estimating diagnostic accuracy 
or comparing accuracy between tests or across participant groups.
27 (84) 31 (97) 88 0.30
Methods
3 The study population: The inclusion and exclusion criteria, setting and locations 
where data were collected.
17 (53) 10 (31) 78 0.57
4 Participant recruitment: Was recruitment based on presenting symptoms, results 
from previous tests, or the fact that the participants had received the index tests or 
the reference standard?
28 (88) 32 (100) 88 NA
5 Participant sampling: Was the study population a consecutive series of participants 
defined by the selection criteria in item 3 and 4? If not, specify how participants 
were further selected.
20 (63) 25 (78) 84 0.64
6 Data collection: Was data collection planned before the index test and reference 
standard were performed (prospective study) or after (retrospective study)?
25 (78) 26 (81) 84 0.52
7 The reference standard and its rationale. 14 (44) 14 (44) 69 0.37
8 Technical specifications of material and methods involved including how and when 
measurements were taken, and/or cite references for
a) index tests and
b) reference standard.
28 (88)
19 (59)
29 (91)
19 (59)
97
75
0.84
0.48
9 Definition of and rationale for the units, cut-offs and/or categories of the results of 
the
a) index tests and the
b) reference standard.
26 (81)
20 (63)
26 (81)
23 (72)
81
78
0.39
0.51
10 The number, training and expertise of the persons executing and reading the
a) index tests and the
b) reference standard.
13 (41)
11 (34)
13 (41)
10 (31)
94
84
0.87
0.65
11 Whether or not the readers of the
a) index tests and
b) reference standard were blind (masked) to the results of the other test and 
describe any other clinical information available to the readers.
9 (28)
8 (25)
10 (31)
12 (38)
84
88
0.63
0.71
12 Methods for calculating or comparing measures of diagnostic accuracy, and the 
statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).
4 (13) 4 (13) 94 0.71
13 Methods for calculating test reproducibility, if done
a) for the index test
b) for the reference standard.
4 (13)
2 (6)
8 (25)
2 (6)
88
94
0.60
0.47
Results
14 When study was performed, including beginning and end dates of recruitment. 17 (53) 17 (53) 100 1.00
15 Clinical and demographic characteristics of the study population (at least 
information on age, gender, spectrum of presenting symptoms).
14 (44) 16 (50) 81 0.63
16 The number of participants satisfying the criteria for inclusion who did or did not 
undergo the index tests and/or the reference standard, describe why participants 
failed to undergo either test (a flow diagram is strongly recommended).
20 (63) 19 (59) 66 0.28
17 Time-interval between the index tests and the reference standard, and any 
treatment administered in between.
7 (22) 9 (28) 81 0.50
18 Distribution of severity of disease (define criteria) in those with the target 
condition, other diagnoses in participants without the target condition.
9 (28) 15 (47) 63 0.23BMC Medical Research Methodology 2006, 6:12 http://www.biomedcentral.com/1471-2288/6/12
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second assessment of 0.39 items (95%CI -0.4 to 1.2). In
17 articles (53%), the total number of reported STARD
items was slightly higher at the second assessment than
the first assessment, while this number was similar in
three articles (9%). The smallest detectable difference was
4.7, which means that the quality of reporting of an indi-
vidual study published after the introduction of the
STARD statement should report a least 4.7 items more
than a study published before the introduction of the
STARD statement, to overcome measurement error. When
sample sizes increase, smaller difference can be detected
as SDD on group level equals SDD individual level/√n.
The inter-assessment reliability of the total number of
reported STARD items was satisfactory (ICC = 0.79 [95%
CI = 0.62, 0.89]). The variance between the 32 articles,
two assessments and the random error were 10.7, -0.01
and 2.8, respectively.
For subgroup analysis on design of the studies, numbers
were too small.
Intra-observer agreement
For the first and second reviewer, the intra-observer agree-
ment for each item of the STARD statement are calculated
and presented in Additional file 1. For the first reviewer,
the intra-observer agreement for all items of the STARD
statement was 83% (Cohen's kappa 0.66) and for the sec-
ond reviewer 82% (Cohen's kappa 0.64). The intra-
observer agreement varied from 56% (item 18) to 100%
(item 14). Low intra-observer agreement (≤ 75% agree-
ment for both observers) was found for item 7, item 16,
item 18, item 19, item 22 and item 23). Except for item
23, these are the same items for which we observed the
highest number of disagreements in the inter-assessment
analysis.
Inter-observer agreement
For the first and second assessment, the inter-observer
agreement for each item of the STARD statement are cal-
culated and presented in Additional file 1. Inter-observer
agreement for all items of the STARD statement was 81%
for the first assessment (Cohen's kappa 0.61) as well as for
Table 2: Inter-assessment agreement: mean of first assessment and second assessment of the quality of reporting of diagnostic 
accuracy studies (n = 32), followed by mean differences between the two assessments, 95% limits of agreement, and smallest 
detectable difference (SDD).
Outcome 
measure
First assessment (A) Second assessment (B) Difference B 
– A
MeandiffAB 
(SDdiffAB)
95% Limits of 
Agreement*
SDD† Systematic 
differences
(95%CI)‡
MeanA (SDA) RangeA MeanB (SDB)R a n g e B
Number of 
reported 
STARD items 
(0–25)
12.08 (3.9) 3.5 – 19 12.47 (3.4) 7 – 19 0.39 (2.4) -4.27, 5.05 4.66 0.39 (-0.4, 
1.2)
SD = Standard Deviation, * 95% Limits of Agreement: mean(diffAB)± 1.96SDdiffAB, † SDD = Smallest Detectable Difference (SDD = 1.96 * SDdiffAB); ‡ 
systematic difference (bias) = MeandiffAB± 1.96 * SDdiffAB/√ n; 95%CI = 95% confidence intervals.
19 A cross tabulation of the results of the index tests (including indeterminate and 
missing results) by the results of the reference standard, for continuous results, the 
distribution of the test results by the results of the reference standard.
24 (75) 24 (75) 75 0.33
20 Any adverse events from performing the index tests or the reference standard. 5 (16) 5 (16) 100 1.00
21 Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% 
confidence intervals).
13 (41) 14 (44) 91 0.81
22 How indeterminate results, missing data and outliers of the index tests were 
handled.
20 (63) 21 (66) 66 0.25
23 Estimates of variability of diagnostic accuracy between subgroups of participants, 
readers or centers, if done.
14 (44) 17 (53) 91 0.81
24 Estimates of test reproducibility, if done.
a) index test
b) reference standard
8 (25)
1 (3)
10 (31)
2 (6)
81
97
0.54
0.65
Discussion
25 Discuss the clinical applicability of the study findings. 31 (97) 31 (97) 94 -0.032
* Data extraction form for assessing the 25 items of the STARD statement and the references of the 32 included articles are available on request of 
the first author; NA = not able to calculate.
Table 1: Number of articles reported the items of the STARD statement at the first and second assessment and for each item the 
percentage agreement between the two assessments and kappa statistics of the two assessments.* (Continued)BMC Medical Research Methodology 2006, 6:12 http://www.biomedcentral.com/1471-2288/6/12
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the second assessment (Cohen's kappa 0.63). Inter-
observer agreement varied from 50% (item 18) to 100%
(item 14, 20, and 24b). At both assessments, most disa-
greements (≤ 75% agreement) between reviewers were
found for item 6, item 7, item 11b, item 15, item 16, item
18, item 19, and item 22.
Discussion
The overall reproducibility of the assessment of the qual-
ity of reporting on diagnostic accuracy studies published
in 12 medical journals with a high impact factor, using the
STARD statement, was found to be good with a Cohen's
kappa statistic of 0.70 and ICC of 0.79. Substantial disa-
greement was found for some items, including (a) the
reporting of the rationale of the reference standard, (b)
the number of included participants that undergo the
index tests and/or the reference standard and description
why participants failed to undergo either test, (c) the dis-
tribution of the severity of the disease in those with the
target condition and other diagnosis in participants with-
out the target condition, (d) a cross tabulation of the
results of the index test by the results of the reference
standard, and (e) how indeterminate results, missing data
and outliers of the index test were handled. The results of
the intra-observer and inter-observer reproducibility
showed low observer agreements (≤ 75%) for the same
items, indicating that reviewers had difficulties with the
assessment of these items. If we had found high intra-
observer but low inter-observer reproducibility, this
would have pointed at different interpretation of the
items. Therefore, these disagreements in our study were
probably not caused by differences in interpretation of the
items, but rather by difficulties in assessing the reporting
of these items in the articles.
Stengel and colleagues found similar results in 62 diag-
nostic accuracy studies on ultrasonography for trauma.
The inter-observer agreement of assessment of STARD
items ranged from poor for specification of the number of
patients who dropped out (58%) to almost perfect for the
specification of the selection criteria (98%). [25]
Although four reviewers acted as second reviewer, we
decided, based on the small number of studies assessed by
these four reviewers, to ignore differences in scoring
between the four reviewers and not calculate stratified
reproducibility statistics. As the agreements of the review-
ers with the first reviewer were comparable, this is unlikely
to have influenced our results.
The presentation of a flow diagram, presenting the design
of the study and the flow of patients through the study,
would be helpful in improving the quality of reporting of
diagnostic accuracy studies, as a flow diagram explicitly
clarifies items that appeared to be difficult to assess. The
optimal flow diagram presents the target population (set-
ting, location and characteristics of potentially eligible
persons and represents the individuals to whom the
results are expected to apply), eligible population (pro-
portion of potential participants who undergo screening
and are eligible to enroll), and the actual research popula-
tion (eligible patients who are willing to participate;
informed consent). The number of participants who did
not satisfy the eligibility criteria, reasons for exclusion,
number of participants who failed to receive one of tests
and the results of the index tests (including indeterminate
and missing results) by the results of the reference stand-
ard representing the true positives, true negatives, false
positives and false negatives can easily be reported in a
flow diagram. The intra- and inter-observer disagreements
regarding item 16 and 22 were caused due confusion
regarding the final research population. If in a study,
patients were excluded from the analysis because they did
not receive one of the tests (missing) and the reasons for
exclusion were not specified, it was unclear whether these
patients belonged to the actual research population or
not.
A large variety in diseases and tests were included in our
study. This was a result of our decision to select all diag-
nostic accuracy studies published in 2000 in general med-
ical journals and discipline specific journals. Although a
pilot evaluation of the quality of reporting was carried out
among all reviewers, no additional criteria were defined
for specification of the severity of all diseases (item 18)
described in the studies. Evaluating the reporting of this
item was affected by the differences in the subjective judg-
ment of the reviewers. A similar observation was made
reporting the rationale of the reference standard. More
detailed specification of these items is possible if the
STARD statement is used to evaluate papers about a spe-
cific subject. Items such as the recruitment period, adverse
events of the tests and presentation of a flow diagram are
less susceptible to subjective judgment of the reviewers,
resulting in higher inter-assessment, intra-observer and
inter-observer agreement.
High inter-assessment agreement was observed for the
reporting of those items that are associated with biased
estimates of diagnostic accuracy, such as the blinding of
the readers of the index and reference test to the results of
the other test and the clinical information and the descrip-
tion of the study population. [26-28] Furthermore, the
results of this reproducibility study indicates the impor-
tance of the need of at least two reviewers who independ-
ently assess the quality of reporting of diagnostic accuracy
studies.
We recommend that the STARD steering committee
should discuss the results of this reproducibility study andBMC Medical Research Methodology 2006, 6:12 http://www.biomedcentral.com/1471-2288/6/12
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decide whether certain items of the STARD statement
should be more clarified in the statement as these items
cause difficulties in the assessment of the quality of
reporting. To our opinion, including a flow diagram in all
reports on diagnostic accuracy studies would be very help-
ful for both readers and reviewers.
As this reproducibility study did yield important informa-
tion for the applicability of the STARD statement, this
could also be the case for other guidelines such as CON-
SORT, QUOROM, MOOSE and STROBE.
Conclusion
In summary, this study shows that agreement in evaluat-
ing the reported STARD items is satisfactory. The evalua-
tion of the quality of reporting of diagnostic accuracy
studies is not trivial, as the assessment of some STARD
items are potentially affected by the subjective judgment
of the reviewers. In order to improve an unequivocal
interpretation of the study design and the flow of patients
through the study, a flow diagram is an indispensable tool
for diagnostic accuracy studies.
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